VYNE Therapeutics Inc. (VYNE)
NASDAQ: VYNE
· Real-Time Price · USD
0.40
-1.04 (-72.22%)
At close: Jul 30, 2025, 3:59 PM
VYNE Therapeutics Income Statement
Financials in USD. Fiscal
year is
January - December.
Fiscal Year | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 |
Period Ending | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 |
Revenue | 202K | 84K | 121K | 198K | 98K | 76K | 114K | 135K | 99K | 6K | 167K | 126K | 178K | 2.29M | 4.09M | 4.26M | 4.12M |
Cost of Revenue | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | 12K | n/a | 903K | 1.05M | 795K | 601K |
Gross Profit | 202K | 84K | 121K | 198K | 98K | 76K | 114K | 135K | 99K | 6K | 167K | 114K | 178K | 1.39M | 3.04M | 3.46M | 3.52M |
Operating Income | -9.2M | -12.77M | -13.09M | -10.4M | -7.38M | -6.83M | -6.23M | -10.32M | -5.88M | -7.98M | -9.33M | -8.29M | -8.69M | -12.04M | 17.78M | -18.78M | -19.43M |
Interest Income | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Pretax Income | -8.6M | -12.01M | -12.16M | -9.39M | -6.24M | -6.15M | -6.07M | -10.04M | -5.61M | -7.75M | -9.26M | -8.23M | -8.69M | -12.02M | -21.29M | -19.92M | -20.55M |
Net Income | -8.61M | -12.02M | -12.16M | -9.41M | -6.25M | -6.19M | -6.58M | -10.06M | -5.62M | -7.76M | -9.46M | -8.48M | 4.67M | -11.57M | -21.29M | -19.92M | -20.55M |
Selling & General & Admin | 3.27M | 3.17M | 2.96M | 3.29M | 3.77M | 3.88M | 3.03M | 3.22M | 3.24M | 3.71M | 3.95M | 4.3M | 4.42M | 8.2M | 13.83M | 15.84M | 16.62M |
Research & Development | 6.12M | 9.68M | 10.25M | 7.31M | 3.71M | 3.02M | 3.32M | 7.23M | 2.73M | 4.28M | 5.55M | 4.11M | 4.45M | 5.24M | 6.98M | 6.41M | 6.33M |
Other Expenses | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | 78K | 52K | -3K | 26K | -35K | -69K | -57K |
Operating Expenses | 9.4M | 12.85M | 13.21M | 10.59M | 7.48M | 6.91M | 6.35M | 10.45M | 5.97M | 7.99M | 9.5M | 8.41M | 8.87M | 13.43M | 20.81M | 22.24M | 22.95M |
Interest Expense | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | 2.34M | n/a | n/a | 3K | n/a | 3.47M | 1.07M | 1.06M |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | -9.49M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 9.4M | 12.85M | 13.21M | 10.59M | 7.48M | 6.91M | 6.35M | 10.45M | 5.97M | 7.99M | 9.5M | 8.41M | 8.87M | 14.34M | 21.86M | 23.04M | 23.55M |
Income Tax Expense | n/a | 4K | n/a | n/a | n/a | 37K | n/a | 20K | 10K | 13K | n/a | n/a | n/a | -448K | 3.44M | 1M | 1M |
Shares Outstanding (Basic) | 42.67M | 42.59M | 42.59M | 42.59M | 42.58M | 31.05M | 3.28M | 3.27M | 3.26M | 2.98M | 3.22M | 3.22M | 3.08M | 2.97M | 2.89M | 2.86M | 2.71M |
Shares Outstanding (Diluted) | 42.67M | 42.59M | 42.59M | 42.59M | 42.58M | 31.05M | 3.28M | 3.27M | 3.26M | 2.98M | 3.22M | 3.22M | 3.08M | 2.97M | 2.89M | 2.86M | 2.71M |
EPS (Basic) | -0.2 | -0.28 | -0.29 | -0.22 | -0.15 | -0.2 | -2.01 | -3.08 | -1.72 | -2.6 | -2.94 | -2.63 | 1.52 | -3.89 | -7.36 | -6.98 | -7.57 |
EPS (Diluted) | -0.2 | -0.28 | -0.29 | -0.22 | -0.15 | -0.2 | -2.01 | -3.08 | -1.72 | -2.6 | -2.94 | -2.63 | 1.52 | -3.89 | -7.36 | -6.98 | -7.57 |
EBITDA | -9.19M | -12.77M | -13.09M | -9.39M | -7.38M | -6.83M | -6.23M | -10.04M | -5.88M | -7.75M | -9.16M | -8.28M | -8.65M | -11.99M | -10.77M | -18.82M | -19.46M |
EBIT | -9.2M | -12.77M | -13.09M | -10.4M | -7.38M | -6.83M | -6.23M | -10.04M | -5.88M | -7.75M | -9.33M | -8.29M | -8.69M | -12.02M | -10.8M | -9.61M | -9.81M |
Depreciation & Amortization | 6K | n/a | n/a | 1M | -777K | -255K | -39.59K | 122.08K | 41.58K | -155K | 171K | 12K | 44K | 26K | 28K | 28K | 27K |